2023-03-30 10:30:00 ET
The stock market is in a precarious place. The sharp rise in both interest rates and bond yields has weighed heavily on most stocks since the first quarter of 2022. A select handful of stocks have been immune to this downward trend, however. Most companies with robust free cash flows and economically insensitive business models have not only escaped this broad sell-off, but they have actually thrived in this pressure-packed environment.
The top-shelf drugmakers Novartis (NYSE: NVS) and Vertex Pharmaceuticals (NASDAQ: VRTX) are two prime examples. Over the prior 15 months, these two large-cap pharmaceutical equities have stormed higher as the broader markets fell into bear territory.
For further details see:
What Bear Market? These 2 Winning Stocks Are Still Worth Buying.